The reason for this is greater treatments with HPV alone but fewer treatments with triage but greater cost of additional testing with triage.The choice of a screen and treat strategy vs screen, triage and treat strategy (such as using VIA as a triage after a HPV DNA test), will depend on the context: the capacity of the health care system to Benefits of primary HPV testing. Primary HR-HPV testing has higher sensitivity for high grade cervical intraepithelial neoplasia (CIN) than primary cytology. This means using primary HR-HPV testing to screen women will identify more women at risk of developing cervical cancer. And it will save more lives by determining a woman’s risk earlier. Background We evaluated the prognostic and diagnostic ability of p16/Ki-67 immunocytochemistry, HPV E6/E7 mRNA testing and HPV DNA assay in triaging ASCUS to find a way to manage cervical lesions more effectively. Methods We conducted a prospective study through follow-up. The detection methods of the three factors: p16/Ki-67 immunocytochemistry conducted by using the CINtec® Plus Kit, E6/E7 HPV screening or HPV/cytology co-testing every 5 years for women age d 30-65 years old [2]. However, decreases in HR HPV positivity rates due to HPV vaccination and additional research have Here we use single-cell RNA-seq to profile both HPV-positive and HPV-negative oropharyngeal tumors, uncovering a high level of cellular diversity within and between tumors. mean ratio of cells A strategy of primary HPV DNA testing with a second triage test at a 5-yearly interval for women living with HIV was more effective at reducing cervical cancer cases and deaths than screening with visual inspection with acetic acid (VIA) every 3 years. The inclusion of a second triage test among women living with HIV who screen HPV-positive
. 5895416832629029822358
